Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneus Ltd. ( (AU:CMB) ) has provided an update.
Cambium Bio Limited has announced significant changes in its Board and corporate governance structure. Mr. Barry Sechos, the long-serving Chairman, is retiring after 13 years, with Dr. Edmund Waller, a co-founder and expert in platelet and stem-cell therapeutics, stepping in as the new Chairman. Additionally, A/Prof Denese Marks, an expert in blood and platelet-based therapeutics, joins the Board as an Independent Non-Executive Director, aligning with the company’s mission to advance its lead biologic, Elate Ocular. The company has also appointed Acclime Australia as its outsourced Company Secretary to support its next growth phase.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company that focuses on developing innovative biologics for ophthalmology and tissue repair applications.
Average Trading Volume: 19,808
Technical Sentiment Signal: Sell
Current Market Cap: A$3.47M
For an in-depth examination of CMB stock, go to TipRanks’ Stock Analysis page.